MorphoSys
Novartis to Consolidate MorphoSys Acquisition with Site Closures and Layoffs
Novartis, MorphoSys, acquisition, consolidation, layoffs, site closures
Novartis’ $2.9B MorphoSys Acquisition Hits Roadblock as Safety Concerns Delay Approval Filing
Novartis, MorphoSys, safety signal, delayed approval, biotech, pharmaceuticals
Incyte Seeks Expanded Approval for Monjuvi Following Successful Phase III Trial in Follicular Lymphoma
Incyte, Monjuvi, follicular lymphoma, Phase III trial, label expansion, tafasitamab, MorphoSys, FDA approval, cancer treatment.
After Incyte’s commercial buy, Novartis shells out 2.7B for cancer specialist MorphoSys
Importal, MorphoSys, Acquisition (action), Incyte